Methods for direct synthesis of compounds having complementary structure to a desired molecular entity and use thereof

• US 6,127,154 A
• Filed: 05/03/1999
• Issued: 10/03/2000
• Est. Priority Date: 02/10/1994
• Status: Expired due to Term

• Current Assignee: KLAUS MOSBACH, CENTER FOR CHEMISTRY AND CHEMICAL ENGINEERING, PURE AND APPLIED BIOCHEMISTRY
• Original Assignee: Karsten Haupt, Klaus Mosbach, Olof Ramstrom, Peter A.G. Cormack
• Inventors: Mosbach, Klaus, Ramstrom, Olof, Haupt, Karsten, Cormack, Peter A. G.
• Primary Examiner(s): KRASS, FREDERICK F
• Application Number:
  US09/303,656
• Time in Patent Office: 519 Days
• Field of Search: 264/108, 264/219, 264/220, 264/221, 264/225, 264/226, 264/227, 264/330, 264/DIG. 44, 264/330.11, 264/331.11, 264/331.16, 264/331.19, 424/78.08, 424/78.37, 526/238.1, 526/238.2, 435/173.1, 435/173.2, 435/173.4, 435/183, 435/188.5, 530/387.1, 530/388.1, 530/388.9, 530/389.8
• US Class Current: 435/173.1
• CPC Class Codes: B01J 20/268 Polymers created by use of a template, e.g. molecularly imprinted polymers
• CPC Class Codes: B82Y 30/00 Nanotechnology for materials or surface science, e.g. nanocomposites
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Compounds which possess a complementary structure to a desired molecule, such as a biomolecule, in particular polymeric or oligomeric compounds, which are useful as in vivo or in vitro diagnostic and therapeutic agents are provided. Also, various methods for producing such compounds are provided. These polymeric or oligomeric compounds are useful in particular as antimicrobial agents, receptor, hormone or enzyme agonists and antagonists.

Claims

1. A method for producing a compound suitable for in vitro or in vivo usage as a diagnostic, therapeutic, purification, separation, or prophylactic agent that possesses a complementary structure to a specific site on a target molecular entity or portion thereof by site-specific molecular imprinting comprising the following steps:

(i) selecting a particular molecular entity to which a compound having a complementary structure is to be produced;

(ii) contacting such molecular entity with one or more complementary monomers under conditions wherein such monomers associate around one or more residues of such molecular entity;

(iii) effecting polymerization of such associated monomers optionally in the presence of at least one crosslinking agent to produce a polymeric coating on the surface of said molecular entity and which possesses a complementary structure to said biological entity or a portion thereof;

(iv) removing said molecule under conditions that result in a polymeric compound that possesses a complementary structure to said molecular entity or portion thereof; and

(v) optionally effecting one or more cleavage and/or dissociation steps to produce compounds that are suitable for in vivo or in vitro usage as a diagnostic, therapeutic, purification, separation and/or prophylactic agent.

2. The method of claim 1, wherein said molecule is immobilized to a support.

3. The method of claim 1, wherein said molecular entity and is selected from the group consisting of a protein, a nucleic acid sequence, a carbohydrate, a peptide, a glycoprotein, a cell, a virus, a pathogen, and a tissue.

4. The method of claim 3, wherein said protein is selected from the group consisting of an enzyme, antigen, antibody, hormone, receptor, and a fragment thereof.

5. The method of claim 1, wherein the crosslinking agent comprises at least one cleavable crosslinker.

6. The method of claim 5, wherein said crosslinker is selected from the group consisting of bis-acrylcystamine, N,N-diallyltartardiamide, N,N-(1,2-dihydroxyethylene) bisacrylamide, N,N'"'"'-bis-(acryloyl)cystamine, N1-(CE)-1-(4-vinylphenyl)methylidene)-4-vinyl aniline, allyl disulfide, and bis-(2-(methacryl, 1-oxyethyl)) disulfide.

7. A method of using the compound in vivo produced according to claim 1 as a therapeutic or diagnostic agent comprising administering to a subject in need of such treatment a therapeutically or diagnostically effective amount of said compound.

8. The method according to claim 1, wherein the molecule to which a compound having a complementary structure is to be produced is insoluble.

9. The method of claim 8, wherein said molecule is an enzyme crystal or a crosslinked enzyme.

10. An improved method of affinity purification which purifies a compound using a compound that specifically binds thereto, wherein the improvement comprises using a compound produced according to claim 1 to effect purification.

11. An improved assay method which includes a competitive affinity ligand wherein the improvement comprises using as the competitive affinity ligand a compound produced according to claim 1.

12. The method of claim 1, wherein the compound produced by said method is suitable for use as an active agent selected from the group consisting of a hormone, enzyme, receptor antagonist or agonist;

gene expression modulator, antimicrobial agent, and an anti-tumor agent.

13. The method of claim 1, wherein the compound which results from said method is subsequently attached to a therapeutic or diagnostic agent.

27. A compound produced according to claim 1.

31. The method of claim 1, wherein the resultant polymer ranges in molecular weight from about 1000 to about 200,000.

32. The method of claim 31, wherein the molecular weight ranges from about 5,000 to 50,000.

33. The method of claim 1, wherein the chain length of the resultant polymer ranges from about 25 to 2500 angstroms.

34. The method of claim 33, wherein the chain length ranges from 250 to 1000 angstroms.

37. The method of claim 1, wherein said polymeric compound is an oligomeric compound.

14. A method for producing a polymeric compound that exhibits complementary structure to a specific site on a cell or virus by site specific molecular imprinting comprising the following steps:

(i) optionally immobilizing said cell or virus to a support;

(ii) coating said optionally immobilized cell or virus with a polymer that is crosslinkable under specific conditions;

(iii) selectively crosslinking the portion of the coating that is proximate to the cell or virus; and

(iv) removing the resultant molecular coating from the cell or virus.

15. The method of claim 14, wherein the polymer is a photocrosslinkable polymer.

16. The method of claim 15, wherein the polymer areas not proximate to the immobilized microbial or mammalian cell are covered with a photomask during photocrosslinking.

17. The method of claim 14, wherein the support is a thin layer support.

18. The method of claim 14, wherein the polymer coating in step (ii) is introduced by a method selected from the group consisting of spray-coating, dip-coating, and spin-coating.

19. The method of claim 14, wherein the resultant polymeric coating is suitable for use as a cell separating material.

20. The method of claim 14, wherein the molecular coating is subsequently cleaved into oligomers which function as anti-microbial agents.

28. A compound produced according to claim 14.

21. A method for producing a compound that has a complementary structure to the active or binding site of a molecular entity by site-specific molecular imprinting comprising the following steps:

(i) providing a support which is coated with a first monomer layer coating;

(ii) applying to said first layer a second layer which comprises at least one crosslinkable monomer which is able to move freely in said second layer;

(iii) exposing said second layer to a molecular entity containing at least one active or binding site and allowing for said crosslinkable monomer to associate around said at least one active site;

(iv) providing a crosslinking agent and effecting crosslinking to produce a crosslinked compound that possesses a complementary structure to said at least one active or binding site; and

(v) recovering said crosslinked compound that possesses a complementary structure to said at least one active or binding site or sites.

22. The method of claim 21, wherein said molecular entity is an enzyme or a receptor.

23. The method of claim 22, wherein the resultant compound functions as an antagonist or agonist.

29. A compound produced according to claim 21.

24. A method for producing a polymeric compound that has a complementary structure to a specific site on a molecular entity by site-specific molecular imprinting which method comprises the following steps:

(i) providing a preformed functionalized polymer that is linear or partially crosslinked and contacting same with a molecular entity such that specific functional groups on the polymer interact covalently or non-covalently with specific residues on the molecular entity;

(ii) allowing for such non-covalent or covalent interactions between the functional groups on the polymer and the molecular entity to equilibrate;

(iii) subjecting the resultant equilibrated covalent or non-covalent complex between the polymer and the molecular entity to at least one of the following steps;

(1) chemically treating the functional groups on the polymer that interact least strongly with the molecular entity by site-selective chemical modification;

(2) chemically treating the functional groups on the polymer that interact most strongly with the molecular entity by site-selective chemical modification; and

/or

(3) crosslinking the polymer;

(iv) separating the molecular entity from the resultant polymer.

25. The method of claim 24, wherein the molecular entity is in solution or immobilized to a support.

26. The method of claim 24, wherein crosslinking is effected using a reversible cleavable crosslinking agent.

30. A compound produced according to claim 25.

38. The method of claim 24, wherein said polymeric compound is an oligomeric compound.

35. A method for producing a compound suitable for in vitro or in vivo usage as a therapeutic agent that possesses a complementary structure to a specific site on a target molecule or portion thereof by site-specific molecular imprinting comprising the following steps:

(i) selecting a particular molecule to which a compound having a complementary structure is to be produced;

(ii) contacting such molecule with one or more complementary monomers under conditions wherein such monomers associate around one or more residues of such molecule;

(iii) effecting polymerization of such associated monomers optionally in the presence of at least one crosslinking agent to produce a polymeric coating which possesses a complementary structure to said specific site of said molecule or a portion thereof;

(iv) removing said molecule to produce a compound that possesses a complementary structure to said specific site of said molecule or portion thereof; and

(v) optionally effecting one or more cleavage and/or dissociation steps to produce a compound that is suitable for in vivo usage as a therapeutic agent.

36. The method of claim 35, wherein said specific site constitutes an active or specific binding site.